Prelude Therapeutics
PRLD
61 hedge funds and large institutions have $129M invested in Prelude Therapeutics in 2024 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 21 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
18.31% more ownership
Funds ownership: 62.29% → 80.6% (+18%)
5% more funds holding
Funds holding: 58 → 61 (+3)
20% less capital invested
Capital invested by funds: $162M → $129M (-$32.9M)
24% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$76.7K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$72.3K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$60.1K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$59.5K |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$57.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$483K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$206K |
| 3 |
Renaissance Technologies
New York
|
-$155K |
| 4 |
Cerity Partners
New York
|
-$154K |
| 5 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
-$149K |
PRLD Hedge Fund Activity: Q2 2024 in Review
61 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q2 2024, worth a combined $129M — down 20% from $162M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PRLD positions and 7 closed out — a net gain of 3 holders — while 16 added to existing stakes and 21 trimmed.
The largest buyer was Y-Intercept (HK), opening a new position worth an estimated $76.7K. The largest seller was Millennium Management, exiting entirely with an estimated $483K sold.
- 61 institutional investors held Prelude Therapeutics (PRLD) as of Q2 2024, up from 58 in Q1 2024.
- Funds reported $129M of Prelude Therapeutics stock for Q2 2024, down 20% quarter-over-quarter.
- 10 funds opened new Prelude Therapeutics positions in Q2 2024 and 7 closed out, a net change of +3 holders.
- The largest Prelude Therapeutics buyer in Q2 2024 was Y-Intercept (HK), an estimated $76.7K added.
- The largest Prelude Therapeutics seller in Q2 2024 was Millennium Management, an estimated $483K sold.
Based on aggregated 13F filings for Q2 2024.